---
layout: post
title: "Determination That Bacitracin for Injection, 10,000 Units/Vial and 50,000 Units/Vial, Was Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-05 19:00:44 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-19995
original_published: 2022-09-15 00:00:00 +0000
significance: 8.00
---

# Determination That Bacitracin for Injection, 10,000 Units/Vial and 50,000 Units/Vial, Was Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 05, 2026 19:00 UTC
**Source:** Federal Register
**Original Published:** September 15, 2022 00:00 UTC
**Document Number:** 2022-19995

## Summary

The Food and Drug Administration (FDA or Agency) has determined that bacitracin for injection, 10,000 units/vial and 50,000 units/vial, was withdrawn from sale for reasons of safety or effectiveness. The Agency will not accept or approve abbreviated new drug applications (ANDAs) for bacitracin for injection.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/09/15/2022-19995/determination-that-bacitracin-for-injection-10000-unitsvial-and-50000-unitsvial-was-withdrawn-from)
- API: https://www.federalregister.gov/api/v1/documents/2022-19995

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
